Drugs / LMP2A-loaded conventional DC vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02115126 Comparator | Dec 2016 → Jan 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma | David Rizzieri, MD | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMP2A-loaded conventional DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02115126 ↗ |
| Modality | Vaccine | “LMP2A-loaded conventional DC vaccine” NCT02115126 ↗ |
| Route | Intravenous | “Vaccines will be administered following standard institutional practice for IV infusions” NCT02115126 ↗ |